Change location:

Healthcare Professionals

Proveca medicines for children

This section is intended for Healthcare Professionals only and contains promotional content.

Sialanar® (320mcg/ml glycopyrronium equivalent to 400mcg/ml glycopyrronium bromide)

Sialanar® received a Paediatric Use Marketing Authorisation (PUMA) in September 2016 for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.

Sialanar® Prescribing Information
Sialanar® Information HPRA

If you would like to find out further information on Sialanar® (including various educational and supporting resources) please visit the Sialanar® website.

Please click here to visit the Sialanar® website

Please see information below to report adverse events in the Republic of Ireland

Adverse events should be reported. Reporting forms and information can be found at: www.hpra.ie.
Adverse events should also be reported to Proveca Limited.
Phone: +44 333 200 1866 E-mail: medinfo@proveca.com

This is our Republic of Ireland website, intended for UK Healthcare Professionals (HCPs). Our global and country sites can be reached by the selection bar in the top right hand corner.